FDA-cleared profile

IB NEURO, VERSION 1.0

IMAGING BIOMETRICS, LLC · MRI · FDA-cleared (510(k))

Authorized purpose: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.

Clinical role
Post-processing perfusion analysis
Images and patients
MRI · Brain
Key limitation
Keep in mind: The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Dynamically acquired MRI datasets from existing MRI systems.
  • Who uses it?Intended users: Trained physician
  • What does the software produce?Output: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
  • What is its most important limitation?Key limitation: The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.

Clinical takeaway. Clinical role: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.

Evidence takeaway. Evidence from the reviewed source record: K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Post-processing perfusion analysis
  • Exact FDA submission
  • Checked 2026-09-05
Required input
Dynamically acquired MRI datasets from existing MRI systems.
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Trained physician
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.
  • Exact FDA submission
  • Checked 2026-09-05

Preserved baseline compatibility statement; current system compatibility requires confirmation.

Evidence summary
K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-v1.0 clinical sensitivity estimate was established.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No exact-v1.0 clinical specificity estimate was established.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K080762 software verification and validation

  • DesignNonclinical software testing summarized for substantial equivalence
  • PopulationSoftware and perfusion-processing verification; no clinical cohort specified
  • Scopeexact submission
  • Tested versionIB Neuro v1.0
  • IndependenceSponsor or vendor study

K080762

Comparison of DSC-MRI Postprocessing Techniques in Predicting Microvascular Histology in Patients with Glioma

  • DesignClinical comparison of IB Neuro and nordicICE DSC-MRI postprocessing with histologic subanalyses
  • Population52 glioma patients with 3 T DSC imaging; subanalyses included 25 recurrent glioblastoma patients and 29 biopsies from 12 patients
  • Scopeproduct family
  • Tested versionIB Neuro; release not identified in the reviewed abstract
  • Samplen=52
  • IndependenceIndependence not established

PMID:26359151 · DOI:10.3174/ajnr.A4451

Preload and non-preload analyses and histologic correlations are contextual; subgroup denominators are not a pooled independent cohort and no v1.0 diagnostic metric is inferred.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-06

Downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Service-level context only: the vendor page for IB Neuro says some institutions use CPT 76498 (unlisted MRI procedure) for advanced quantitative and perfusion MRI analyses performed with IB Neuro, and notes AMA Category III codes 0865T and +0866T (effective 2024-01-01) for quantitative brain MRI analysis. The page does not state that any payer covers or pays for IB Neuro and gives no amount.
  • Product family
  • Checked 2026-10-26

Vendor page read 2026-10-26. It names IB Neuro without a version, so it is applied as product-family context to this version 1.0 entry. Eligibility depends on payer policy, site of service and documentation.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Dynamically acquired MRI datasets from existing MRI systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · IB Neuro v1.0: K080762 clearance and 510(k) summary

  2. Routing

    Source context, not route validation: Exports perfusion parameter maps as DICOM images to PACS for later viewing; supports interactive voxel time curves and arterial-input-function selection.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · IB Neuro v1.0: K080762 clearance and 510(k) summary

  3. AI processing

    Source context, not route validation: The summary describes an OsiriX plug-in and a platform-independent base library for incorporation into viewing, CAD or PACS applications.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 · IB Neuro v1.0: K080762 clearance and 510(k) summary

  4. Returned objects

    Source context, not route validation: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · IB Neuro v1.0: K080762 clearance and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · IB Neuro v1.0: K080762 clearance and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The summary describes an OsiriX plug-in and a platform-independent base library for incorporation into viewing, CAD or PACS applications.
  • Exact FDA submission
  • Checked 2026-09-05
Integration
Exports perfusion parameter maps as DICOM images to PACS for later viewing; supports interactive voxel time curves and arterial-input-function selection.
  • Exact FDA submission
  • Checked 2026-09-05
Training
The 510(k) summary states that the generated parametric perfusion maps, when interpreted by a trained physician, may yield information useful in the assessment of the patient.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

PACS export

Perfusion maps are exported as DICOM images for PACS viewing.

exact submission · checked 2026-09-05

Legacy host architecture

OsiriX plug-in with a platform-independent base library described for other medical-image applications.

exact submission · checked 2026-09-05
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K080762
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2008-05-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-05Last searched
19Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored metadata screened and primary abstract reviewed. Relevant IB Neuro glioma study retained as product-family context; no exact v1.0 linkage or product-wide numeric accuracy claim. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, peer reviewed literature, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not publicly available - checked 2026-09-05 - Exact FDA submission

    A specific care setting and age restriction were not established in the reviewed v1.0 summary.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    The reviewed current product page does not establish a v1.0 license, support or upgrade price.

  • Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission

    Legacy and current product licensing terms may differ; no pricing model is established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    The 2008 summary does not establish current host security, patch support or a scoped certification for v1.0.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Current maintenance and clinical monitoring arrangements for the legacy release were not established.

9 sources - 3 history items

Source ledger

  1. IB Neuro v1.0: K080762 clearance and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: purpose, clinicalUse, modality, anatomy, input, output, deployment, integration, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. IB Neuro model card (K080762)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. IB Neuro current product family

    Imaging Biometrics - Accessed 2026-09-05

    Scope: productFamilyContext

  8. Comparison of DSC-MRI Postprocessing Techniques in Predicting Microvascular Histology in Patients with Glioma

    American Journal of Neuroradiology / U.S. National Library of Medicine - Published 2015-09-10 - Accessed 2026-09-05

    Scope: evidenceStudies, productFamilyContext

  9. Imaging Biometrics: CPT Codes and the Evolving Reimbursement Landscape

    Imaging Biometrics - Accessed 2026-10-26

    Scope: reimbursement

Research history

  1. K080762 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K253489

Swoop® Portable MR Imaging® System

Hyperfine, Inc.

Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.

Modality
MRI
Anatomy
Brain
Decision
2025-12-12

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history